Crizotinib: A Breakthrough for Targeted Therapies in Lung Cancer

@inproceedings{Kwon2012CrizotinibAB,
  title={Crizotinib: A Breakthrough for Targeted Therapies in Lung Cancer},
  author={Jennifer M Kwon and Alison K Meagher},
  booktitle={Journal of the advanced practitioner in oncology},
  year={2012}
}
J Adv Pract Oncol 2012;3:267–272 Lung cancer is the leading cause of cancer-related mortality in the United States, with approximately 226,160 new cases of lung and bronchial cancer predicted to be diagnosed in 2012, along with approximately 160,340 deaths due to the disease (Siegel, Naishadham, & Jemal, 2012). Worldwide, approximately 1.6 million new cases of lung cancer are diagnosed every year, and 1.38 million deaths were recorded in 2008 (Ferlay et al., 2010). The majority of non–small… CONTINUE READING
0 Extracted Citations
14 Extracted References
Similar Papers

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 14 references

Xalkori (crizotinib) package insert

  • Pfizer.
  • Retrieved from http://labeling.pfizer.com…
  • 2011
Highly Influential
10 Excerpts

v.1.2, Cancer Incidence and mMortality Worldwide: IARC CancerBase. Internationa; Agency for Research on Cancer

  • J. Ferlay, H. R. Shine, F. Bray, D. Foran, C. Mathers, D. M. Parkin
  • GLOBOCAN
  • 2010
Highly Influential
2 Excerpts

NCCN Guidelines for Non-Small Cell Lung Cancer

  • National Comprehensive Cancer Network.
  • Retrieved from http://www.nccn.org/professionals…
  • 2011

Similar Papers

Loading similar papers…